Transcript elisa

Monoclonal
Antibody
Prepared by:
AMER SAAD AL-ALI
ABDUALLAH SAUD AL-SHETELY
TAREQ NAFEA AL-HARBY
Discovery

In the 1970s, the B-cell cancer myeloma was known, and it was understood
that these cancerous B-cells all produce a single type of antibody. This was
used to study the structure of antibodies, but it was not possible to produce
identical antibodies specific to a given antigen.

The process of producing monoclonal antibodies invented by Georges
Köhler and César Milstein in 1975; they shared the Nobel Prize in
Physiology or Medicine in 1984 for the discovery.

The key idea was to use a line of myeloma cells that had lost their ability to
secrete antibodies, and come up with a technique to fuse these cells with
healthy antibody producing B-cells.
Definition

MCA are antibodies that are identical because they were produced
by one type of immune cell (B cell), all clones of a single parent
cell. Given any substance, it is possible to create monoclonal
antibodies that specifically bind to that substance; they can then
serve to detect or purify that substance. This has become an
important tool in biochemistry, molecular biology and medicine.
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Step 1: - Immunization Of Mice & Selection Of Mouse
Donor For Generation Of Hybridoma cells
ANTIGEN ( Intact cell/
Whole cell membrane/
micro-organisms ) +
ADJUVANT
(emulsification)
Ab titre reached in Serum
Spleen removed
(source of cells)
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Step 2: - Screening Of Mice For Antibody Production
After several
weeks of
immunization
Serum Antibody Titre Determined
(Technique: - ELISA / Flow cytometery)
Titre too low
BOOST
(Pure antigen)
Titre High
BOOST 2 weeks
(Pure antigen)
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Step 3: - Preparation of Myeloma Cells
+ 8 - Azaguanine
Myeloma Cells
Immortal Tumor Of Lymphocytes
Myeloma Cells
HGPRTHigh Viability & Rapid Growth
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Step 4: - Fusion of Myeloma Cells with Immune Spleen Cells
&
Selection of Hybridoma Cells
PEG
FUSION
SPLEEN CELLS
MYELOMA CELLS
Feeder Cells
Growth Medium
1.
HYBRIDOMA CELLS
ELISA PLATE
2.
HAT Medium
Plating of Cells in
HAT selective
Medium
Scanning of Viable
Hybridomas
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Step 5: - Cloning of Hybridoma Cell Lines by “ Limiting
Dilution” or Expansion
A. Clone Each +ve Culture
B. Test Each Supernatant for Antibodies
C. Expand +ve Clones
Tissue
Culture
Method
Mouse
Ascites
Method
PRODUCTION OF MONOCLONAL ANTIBODY
HYBRIDOMA TECHNOLOGY
Mca.swf
Applications of Monoclonal
Antibodies

Diagnostic Applications
Biosensors & Microarrays

Therapeutic Applications
Transplant rejection
Cardiovascular disease
Cancer
Infectious Diseases
Inflammatory disease

Clinical Applications
Purification of drugs, Imaging the target

Future Applications
Fight against Bioterrorism
Monoclonal antibodies for cancer
treatment
Three mechanisms that could be responsible for the cancer
treatment.
A.
mAbs act directly when binding to a cancer specific
antigens and induce immunological response to cancer
cells. Such as inducing cancer cell apoptosis, inhibiting
growth, or interfering with a key function.
B.
mAbs was modified for delivery of a toxin, radioisotope,
cytokine or other active conjugates.
C.
it is also possible to design bispecific antibodies that can
bind with their Fab regions both to target antigen and to a
conjugate or effector cell
mAbs treatment for cancer cells
ELISA
Enzyme Linked Immunosorbent
Assay
What is ELISA?

ELISA is a biochemical technique used
mainly in immunology to detect the
presence of an antibody or an antigen in a
sample.

The ELISA has been used as a diagnostic
tool in medicine and plant pathology.
The principle of (ELISA)

It is a solid phase assay that requires the
separation of reagents.

The principle depend on the type of
ELISA(direct or indirect)
Applications

Because the ELISA can be performed to
evaluate either the presence of antigen or the
presence of antibody in a sample, it is a useful
tool both for determining serum antibody
concentrations (such as with the HIV test) and
also for detecting the presence of antigen.

It has also found applications in the food
industry in detecting potential food allergens
such as milk, peanuts and eggs.

The ELISA test, or the enzyme immunoassay (EIA),
was the first screening test commonly employed for
HIV.

It has a high sensitivity. In an ELISA test, a person's
serum is applied to a plate to which HIV antigens have
been attached. The plate is then washed to remove
other components of the serum. Then an antibody
applied to the plate, followed by another wash. This
antibody is chemically linked in advance to an enzyme.

A substrate for the enzyme is applied, and catalysis by
the enzyme leads to a change in color or fluorescence.

ELISA results are reported as a number either positive
or negative result.
Positive Negative
Control Control
1.689




0.153
Patient A Patient B Patient C
O.055
0.412
1.999
Assay
Control
0.123
Above is ELISA data from three patients. Numbers
are expressed as optical density at 450 nm:
Positive result ≥0.500.
0.300 to 0.499 are indeterminate and need to be
retested.
Negative ≤0.300.
Anim0100.swf
Reference
MedLinePlus.
"HIV ELISA/western blot." U.S. National Library of Medicine.
Last accessed April 16, 2007 .
http://www.nlm.nih.gov/medlineplus/ency/article/003538.htm
Lequin
R (2005). "Enzyme immunoassay (EIA)/enzyme-linked immunosorbent
assay (ELISA).". Clin. Chem. 51 (12): 2415-8. PMID 16179424.

Köhler, G., and Milstein, C. Continuous cultures of fused cells Secreting
antibodies of predefined specificity. Nature, 256: 495, (1975).
Koprowski,
H., Steplewski, Z., Herlyn, D., and Herlyn, M. Production of
monoclonal antibody against human melanoma by somatic cell hybrids. Proc.
Nat. Acad. Sci. USA. 75: 3405, (1978).